🇺🇸 FDA

Drug profile · INN

selinexor

NEXPOVIO

approved L01XX66
US status
approved
Patents linked
6
News articles
0

Quick answer

selinexor (NEXPOVIO) is an FDA-listed pharmaceutical active ingredient. Associated with Karyopharm Therapeutics. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN selinexor
Brand NEXPOVIO
Route ORAL
Formulation TABLET
ATC code L01XX66
Originator Karyopharm Therapeutics

Related patents

Search patents →

  1. US 12371420

    Polymorphs of Selinexor

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11807629

    Polymorphs of Selinexor

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11753401

    Polymorphs of Selinexor

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11746102

    Polymorphs of selinexor

    Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11078190

    Polymorphs of selinexor

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10519139

    Polymorphs of Selinexor

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is selinexor?

selinexor (NEXPOVIO) is an FDA-listed pharmaceutical active ingredient. Associated with Karyopharm Therapeutics. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for selinexor?

NEXPOVIO is a marketed brand name for selinexor. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of selinexor?

selinexor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.